A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of Brodalumab in Subjects With Axial Spondyloarthritis
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Brodalumab (Primary)
- Indications Ankylosing spondylitis; Axial spondyloarthritis; Non-radiographic axial spondyloarthritis
- Focus Therapeutic Use
- Sponsors Kyowa Kirin
- 12 Sep 2022 Results assessing long-term efficacy and safety of brodalumab in patients with axial spondyloarthritis, published in the Rheumatology.
- 07 Apr 2021 Results reporting the interim analysis efficacy and safety results of brodalumab vs placebo from the 16-week double-blind randomised period. published in the Annals of the Rheumatic Diseases
- 27 Nov 2020 According to a Kyowa Kirin media release, LUMICEF was granted the supplemental approval for the treatment of ankylosing spondylitis (AS) 1 and non-radiographic axial spondyloarthritis (nr-axSpA) 2 in Japan.